KKR mulls teaming with Japan state fund on Panasonic unit stake: media

Panasonic Corp's President, Kazuhiro Tsuga (R), speaks during a news conference at the company's office in Tokyo March 28, 2013.

Credit: Reuters/Yuya ShinoBy Junko Fujita and Taiga Uranaka

TOKYO | Fri Sep 13, 2013 3:48am EDT

TOKYO (Reuters) - KKR & Co LP is considering teaming up with a state-backed Japanese investment fund to secure a stake in Panasonic Corp's healthcare business, media reported, although people familiar with the matter said the U.S. firm has not approached the fund yet.

A purchase, which could be worth $1.5 billion, would mark the private-equity firm's largest investment in a Japanese company. Last year KKR sought a controlling stake in chipmaker Renesas Electronics Corp but lost out to a group led by the state-backed Innovation Network Corp of Japan.

In its bid this time for the Panasonic unit, Bloomberg and the Wall Street Journal reported, KKR is seeing to assuage local misgivings about foreign buyout firms by considering investing with the government-private fund.

But people familiar with the process said the U.S. firm has not approached the Japanese fund. Two people said teaming up with INCJ is one of various options KKR could pursue.

The people said KKR, which recently raised a $6 billion Asia fund, had enough cash to make the purchase alone.

KKR and INCJ declined to comment.

Sources familiar with the matter told Reuters last week that KKR was set to gain preferential negotiating rights for the majority stake in Panasonic Healthcare Co, which makes blood-sugar monitoring equipment and electronic medical record-keeping systems.

KKR and other foreign buyout firms have struggled to secure deals in Japan amid suspicion they will strip assets and lay off workers to gain the biggest possible return on their investments.

Panasonic, which has lost $15 billion over the past two years, is offloading a majority stake in the profitable healthcare unit as it pulls back from outlying businesses and loss-making consumer electronics to focus on automotive components, appliances, industrial machinery and other fields where it is a leading manufacturer.

In the financial year ended in March, Panasonic Healthcare made 8.7 billion yen in operating income on 134.3 billion yen in sales, giving it an operating profit margin of 6.5 percent.

(Additional reporting by Emi Emoto, Stephan Aldred, Chikafumi Hodo, Reiji Murai and Tim Kelly; Writing by William Mallard; Editing by Chris Gallagher)

View the original article here

Sanofi could acquire L'Oreal's stake, buy more of Regeneron

An employee walks into an office of French drugmaker Sanofi in Shanghai August 2, 2013.

Credit: Reuters/Aly Song

By Natalie Huet and Ben Hirschler

PARIS/LONDON | Fri Sep 13, 2013 7:20pm EDT

PARIS/LONDON (Reuters) - Repurchasing L'Oreal's 9 percent stake in Sanofi might make sense for the French drugmaker if the $12 billion holding is put up for sale, Sanofi's chief executive said on Friday.

Chris Viehbacher told an investor conference the group had the resources to do "opportunistic" share buybacks, as well as making bolt-on acquisitions and potentially increasing its stake in U.S. biotech firm Regeneron Pharmaceuticals.

Shares in Regeneron jumped more than 5 percent to an all-time high of $288.50 in New York after his comments, also buoyed by Lazard Capital Markets and RBC raising their price targets for the stock. Sanofi and L'Oreal shares were little changed.

Speculation over the fate of L'Oreal's stake in Sanofi has been fuelled by last month's comments from L'Oreal's CEO that the cosmetics company could buy back the 23-billion-euro ($30-billion) stake Nestle holds in it if L'Oreal in turn sold the 9-billion-euro stake it owns in Sanofi.

The comments have weighed on Sanofi shares, already dragged down by disappointing quarterly results, but some analysts say the drugmaker could use the opportunity to repurchase the shares with cheap debt, thereby boosting its earnings.

Asked about his potential interest in buying back L'Oreal's stake from next year, Viehbacher said it was difficult to comment because the issue was highly conditional.

"We certainly have cash flow to do some things," he told a Bank of America Merrill Lynch healthcare conference in London.

"Whether we would intervene in that or not is going to be a function of - if it does happen - what at that given point in time is the best use of capital. It may well be opportune to have a look at it."

Restrictions on Nestle selling its L'Oreal stake end in April.

More generally, Viehbacher said he did not exclude other share buybacks, but said these would depend on opportunities for acquisitions.

He said Sanofi could also look at raising its stake in Regeneron to as much as 30 percent. Sanofi holds about 16 percent of Regeneron and said in February it has the right to increase this to a maximum 30 percent under its decade-long partnership with Regeneron.

"The Regeneron relationship has become extremely productive for us," Viehbacher said. "Over time, it could well make sense to build our stake up to 30 percent. How fast we do that, whether or not we do that is a function of a number of different factors - but it is a bulky chunk of money to use."

Regeneron's market value is about $27 billion.

Regeneron is best known for its eye drug Eylea, co-marketed with Bayer. But it has also successfully developed the cancer treatment Zaltrap with Sanofi and is working with the French group on a new kind of cholesterol drug.

The drug, which is in late-stage trials, has cut levels of "bad" LDL cholesterol by 60 percent through a new mechanism - blocking a protein called PCSK9.

(Editing by Louise Ireland and Bob Burgdorfer)

View the original article here